Atlas Trials

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Clinical trial NCT06196827 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06196827
Sponsor
Innostellar Biotherapeutics Co.,Ltd
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Inherited Retinal Dystrophy Associated With RPE65 Mutations
Start date
2022-07-02
Primary completion
2023-12-06
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.